Ian McCubbin OBE Announced as Chair of the RoslinCT Board of DirectorsMarch 26th 2019

Find out more

RoslinCT, a leading cell and gene therapy contract manufacturing organisation, is pleased to announce the appointment of Ian McCubbin OBE as Chair the Board of Directors. Ian brings a wealth of industry experience to the position.

Janet Downie, CEO of RoslinCT, said: “I am delighted that Ian has accepted this prominent role in RoslinCT. We are already benefiting from the vast experience that Ian has brought to the company and look forward to our future expansion with him in place as Chairman of the Board.”

Ian is a pharmacist with 30 years’ experience in the Pharmaceutical industry working for GSK, Merck Generics and IVAX. Ian’s role at GSK as SVP North America, Japan & Global Pharma Supply within the Global Manufacturing & Supply Division included responsibility for 17 factories and 7,000 employees, whose objective was to supply the new product pipeline and the majority of the pharmaceutical sales. Ian retired from this role in 2017 and has since been very active in the Advanced Therapy field. He chaired the Advanced Therapy Manufacturing Task Force whose Action Plan to ‘anchor’ commercial scale manufacturing in the UK has been adopted in full as part of the Life Sciences Industrial Strategy. From there Ian went on to chair the Manufacturing Advisory Board for wave 1 of the Industrial Strategy Challenge Fund, a position he still holds.

RoslinCT would like to extend its gratitude to Malcolm Bateman for his dedication as Chairman over the years and is delighted that he will remain as a non-executive director with the enormous experience he holds. This dynamic and experienced board will be a tremendous asset to the business and continue RoslinCT’s exciting journey and expansion.

END

For more information, please contact:

Janet Downie CEO
Tel: +44 (0)131 658 5180
Email: janet.downie@roslinct.com
Web: www.roslinct.com

About RoslinCT

RoslinCT is a leading Contract Development and Manufacturing Organisation (CDMO), offering a range of integrated services from technology transfer, process and assay development through to GMP manufacturing, storage, QP certification and batch release of cell-based therapies for clinical trials.

RoslinCT has a vision to lead the field in cell and gene therapy manufacturing and be the global partner of choice, building success on expert knowledge, progressive partnerships and with drive to deliver life-changing cell-based products to patients in need. This together with a passion for innovation and a flexible and personalised approach enables RoslinCT to engage with leading cell and gene therapy developers and to provide support at every step of the cell therapy development journey.

For more information please visit www.roslinct.com

Inside Media

Get In Touch

NINE Edinburgh BioQuarter, 9 Little France Road
Edinburgh, United Kingdom, EH16 4UX


+44 (0) 131 658 5180